Orion is a globally operating Finnish pharmaceutical company - a builder of well-being.
About OrionStock exchange releases
- 9/20/2023 Change in Orion Group's Half-Year Financial Report 2024 publication date
- 9/4/2023 24 000 Orion Corporation A shares converted into B shares
- 8/22/2023 Change in Orion Group Executive Management Board as of February 1st, 2024 – Julia Macharey appointed Senior Vice President, People & Culture
- 7/17/2023 Orion Group Half-Year Financial Report 1–6/2023
Press releases
- 7/31/2023 European Commission approval of Ztalmy® (ganaxolone) for the adjunctive treatment of epileptic seizures associated with CDKL5 deficiency disorder
- 7/4/2023 Orion publishes Half-Year Financial Report for January–June 2023 on Monday 17 July 2023
- 6/28/2023 Orion invests EUR 30 million to increase production capacity in Finland
- 5/25/2023 Orion hosts its Capital Markets Day today, May 25, 2023, in Helsinki
Latest articles
All articles
Inke Tirkkonen: The Phase1 trainee programme has allowed me to e...
9/29/2023
We are Orion
Internal mobility has enabled Ville, Master of Science in mechan...
9/29/2023
We are Orion
Maija Väätäjä: The people and truly meaningful work have been th...
9/21/2023
We are Orion
What is a generic medicine – and what is good to know about it?
9/21/2023
Your Health
Damla Serper: As a Phase1 trainee, I have been happy to work on ...
9/15/2023
We are Orion
